Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of subcutaneous anifrolumab plus standard therapy versus placebo plus standard therapy in adults with polymyositis or dermatomyositis
CTR20243503Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of anifrolumab in Autoimmune Myopathies, polymyositis (PM), dermatomyositis (DM), sponsored by AstraZeneca. Started Dec 2024; status: active.
02
Drugs
anifrolumab
03
Conditions
Autoimmune Myopathiespolymyositis (PM)dermatomyositis (DM)
Beyond the preview
Go deeper on CTR20243503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243503.